Quest Diagnostics (DGX) Set to Announce Quarterly Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) will be releasing its earnings data before the market opens on Tuesday, October 22nd. Analysts expect Quest Diagnostics to post earnings of $2.27 per share for the quarter. Quest Diagnostics has set its FY 2024 guidance at 8.800-9.000 EPS and its FY24 guidance at $8.80-9.00 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.04. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same period in the previous year, the business earned $2.30 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Trading Up 0.2 %

Shares of DGX opened at $149.00 on Tuesday. The firm’s fifty day moving average is $152.57 and its two-hundred day moving average is $143.64. The stock has a market cap of $16.55 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. Quest Diagnostics has a 52-week low of $120.87 and a 52-week high of $159.36.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be issued a $0.75 dividend. The ex-dividend date is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a yield of 2.01%. Quest Diagnostics’s payout ratio is 40.38%.

Analyst Upgrades and Downgrades

DGX has been the subject of several recent research reports. StockNews.com cut Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, October 7th. Evercore ISI began coverage on shares of Quest Diagnostics in a research report on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price objective for the company. Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $165.00 in a report on Wednesday, July 10th. Robert W. Baird increased their price objective on Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Piper Sandler raised their target price on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a research note on Monday, July 29th. Ten investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $154.92.

Insider Activity

In other news, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the sale, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the completion of the sale, the senior vice president now directly owns 5,019 shares of the company’s stock, valued at $718,118.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Karthik Kuppusamy sold 1,990 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at $1,756,206.34. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.